Sunmax Biotechnology Co Ltd (4728) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) has a cash flow conversion efficiency ratio of 0.111x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$160.84 Million ≈ $5.07 Million USD) by net assets (NT$1.44 Billion ≈ $45.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4728 market cap overview for the company's overall valuation and market capitalisation.
Sunmax Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Sunmax Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sunmax Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunmax Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Explore Sunmax Biotechnology Co Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nankang Rubber Tire Corp Ltd
TW:2101
|
0.166x |
|
M31 Technology Corp
TWO:6643
|
-0.017x |
|
Dodla Dairy Limited
NSE:DODLA
|
0.024x |
|
Shandong Mining Machinery Group Co Ltd
SHE:002526
|
0.049x |
|
Jiahe Foods Industry Co. Ltd.
SHG:605300
|
0.014x |
|
Kim Loong Resources Bhd
KLSE:5027
|
0.060x |
|
Mavi Giyim Sanayi Ve Ticaret AS
IS:MAVI
|
0.073x |
|
Qingdao Kutesmart Co Ltd
SHE:300840
|
0.118x |
Annual Cash Flow Conversion Efficiency for Sunmax Biotechnology Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Sunmax Biotechnology Co Ltd from 2015 to 2024. View today's stock price for Sunmax Biotechnology Co Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.51 Billion ≈ $47.66 Million |
NT$397.37 Million ≈ $12.52 Million |
0.263x | -55.86% |
| 2023-12-31 | NT$1.43 Billion ≈ $44.93 Million |
NT$848.56 Million ≈ $26.73 Million |
0.595x | +129.93% |
| 2022-12-31 | NT$1.33 Billion ≈ $41.75 Million |
NT$342.97 Million ≈ $10.81 Million |
0.259x | +8.88% |
| 2021-12-31 | NT$1.02 Billion ≈ $32.25 Million |
NT$243.28 Million ≈ $7.66 Million |
0.238x | -45.41% |
| 2020-12-31 | NT$888.84 Million ≈ $28.00 Million |
NT$386.97 Million ≈ $12.19 Million |
0.435x | +1.78% |
| 2019-12-31 | NT$676.83 Million ≈ $21.32 Million |
NT$289.51 Million ≈ $9.12 Million |
0.428x | +174.90% |
| 2018-12-31 | NT$648.01 Million ≈ $20.42 Million |
NT$100.83 Million ≈ $3.18 Million |
0.156x | +140.26% |
| 2017-12-31 | NT$572.70 Million ≈ $18.04 Million |
NT$37.09 Million ≈ $1.17 Million |
0.065x | +116.86% |
| 2016-12-31 | NT$555.29 Million ≈ $17.49 Million |
NT$16.58 Million ≈ $522.46K |
0.030x | +172.98% |
| 2015-12-31 | NT$558.24 Million ≈ $17.59 Million |
NT$-22.84 Million ≈ $-719.74K |
-0.041x | -- |
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.